Hämostaseologie, Inhaltsverzeichnis Hamostaseologie 2017; 37(03): 216-218DOI: 10.5482/HAMO-16-07-0028 Highlight Schattauer GmbH A new era of treatment for patients with haemophilia A?Eine neue Ära in der Behandlung von Patienten mit Hämophilie A?Authors Institutsangaben Robert Klamroth 1 Zentrum für Hämophilie und Hämostaseologie, Vivantes – Netzwerk für Gesundheit, Berlin, Germany Artikel empfehlen Abstract Volltext als PDF herunterladen(opens in new window) Keywords Keywordshaemophilia A - inhibitor - prophylaxis - bispecific antibody Schlüsselwörter SchlüsselwörterHämophilie A - Inhibitor - Prophylaxe - bispezifischer Antikörper Referenzen References 1 Sampei Z, Igawa T, Soeda T. et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 08 (02) e57479. 2 Muto A, Yoshihashi K, Takeda M. et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124 (20) 3165-3171. 3 Uchida N, Sambe T, Yoneyama K. et al. A first-inhuman phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641. 4 Shima M, Hanabusa H, Taki M. et al. Factor VIIIMimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053.
